Mostrar el registro sencillo del ítem

A proposal to study the safety and efficacy of psilocybe cubensis in preclinical and clinical studies as a therapeutic alternative for major depressive disorder

dc.creatorEscamilla, Raules_ES
dc.creatorGonzález-Trujano, María Evaes_ES
dc.creatorGonzález Mariscal, Jesús M.es_ES
dc.creatorTorres-Valencia, Jeús Martínes_ES
dc.creatorGuzmán-González, Héctores_ES
dc.creatorVega, José Luises_ES
dc.creatorLoizaga-Velder, Anjaes_ES
dc.date2023
dc.date.accessioned2025-03-20T16:49:52Z
dc.date.available2025-03-20T16:49:52Z
dc.date.issued2023
dc.identifierJC23NC23es_ES
dc.identifier.issn0279-1072
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/8257
dc.identifier.urihttps://doi.org/10.1080/02791072.2023.2246459
dc.descriptionThe pharmacological treatment of depression consists of taking antidepressant drugs for prolonged periods; its modest therapeutic effect can often be associated with significant adverse effects, while its discontinuation can lead to relapses. Psilocybin is today a novel and breakthrough therapy for major depression. It is a natural alkaloid in Psilocybe mushrooms, which are endemic to Mexico. Research on a larger scale is lacking in various populations, including the Mexican people. This proposal contemplates the experimental design of a preclinical (toxicity and pharmacological evaluation of an extract in mice) and clinical study by including the chemical analysis of a species of Psilocybe cubensis mushroom to characterize its main constituents. The clinical study will consider the safety evaluation by exploring tolerated doses of Psilocybe cubensis by measuring pharmacokinetic parameters after oral administration in healthy adults and an open trial on a sample of patients with major depressive disorder to assess the safety and efficacy of fully characterized Psilocybe cubensis in a two-single doses treatment, (with assisted psychotherapy), compared with the traditional care model at the Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz in Mexico City. This report presents the design of a research project with preclinical and clinical experimental components.es_ES
dc.formatPDFes_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francises_ES
dc.relation55(5):570-580
dc.rightsAcceso Cerradoes_ES
dc.titleA proposal to study the safety and efficacy of psilocybe cubensis in preclinical and clinical studies as a therapeutic alternative for major depressive disorderes_ES
dc.typeArtículoes_ES
dc.contributor.affiliationServicios Clínicos. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (INPRFM), Mexico city, Mexico
dc.contributor.emailrescam01@gmail.com (Raul Escamilla)
dc.relation.jnabreviadoJ PSYCHOACTIVE DRUGS
dc.relation.journalJournal of Psychoactive Drugs
dc.identifier.placeEstados Unidos
dc.date.published2023
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.eissn2159-9777
dc.identifier.doi10.1080/02791072.2023.2246459
dc.subject.kwMajor depression
dc.subject.kwPsilocybe mushrooms
dc.subject.kwPsilocybin
dc.subject.kwPsychedelic therapy


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem